Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up...
Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half Adjusted Non-IFRS Net Profit Attributable...
EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS
Key Takeaways Wildfire smoke may be particularly hazardous to brain health, according to a 10-year study of more than 1.2 million southern Californians. Exposure to wildfire smoke increases the risk of being diagnosed with dementia more than other forms of air pollution. The risk of exposure to fine particulate...
Akeso’s sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for first-line treatment of PD-L1 positive (PD-L1 TPS≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC), has been accepted...
NUS researchers develop a novel technique to fabricate three-dimensional circuits for advanced electronics
CHARM3D paves the way for the efficient printing of free-standing 3D structures that offer high electrical conductivity, self-healing capabilities and recyclability — a boon for electronics in healthcare, communications and security SINGAPORE, July 29, 2024 /PRNewswire/ -- Unlike traditional printed circuit boards, which are flat, 3D circuitry enables components to be stacked and...
Global Icon Malala Yousafzai to Headline APACMed’s MedTech Forum in Singapore
SINGAPORE, July 29, 2024 /PRNewswire/ -- APACMed is thrilled to announce that Nobel Laureate and global icon Malala Yousafzai will take centre stage at this year's MedTech Forum, taking place on September 5th and 6th at the Suntec Convention Centre. This highly anticipated event focuses squarely on Artificial Intelligence (AI) and how...
111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 – Conference Call to Follow
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2024, before the...
A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST
- Awareness and early-stage detection of Mild Cognitive Impairment (MCI) for prevention. - Free Visual Cognitive Assessment Test (VCAT) screening at selected CARiNG Pharmacy Malaysia outlets. KUALA LUMPUR, Malaysia, July 29, 2024 /PRNewswire/ -- A. Menarini, a wholly owned subsidiary of the Menarini Group − an Italian pharmaceutical company with more than 135 years of history is embarking on a...
ALZHEIMER’S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES
Key Takeaways Blood tests that accurately and reliably detect Alzheimer's hallmark brain changes signal a shift to simpler, more accurate and earlier detection and diagnosis, potentially superseding current methods that are expensive, invasive and not always accessible. A blood test was around 90% accurate in identifying Alzheimer's disease in patients...
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective disorder in adults as...
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with...
The positive CHMP opinion is based on results from the Phase II PHAROS trial, which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication The European Commission decision for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) is expected later this year....
